202 related articles for article (PubMed ID: 19113865)
1. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN.
Liu Z; Yan Y; Chin FT; Wang F; Chen X
J Med Chem; 2009 Jan; 52(2):425-32. PubMed ID: 19113865
[TBL] [Abstract][Full Text] [Related]
2. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
3. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging.
Li ZB; Wu Z; Chen K; Ryu EK; Chen X
J Nucl Med; 2008 Mar; 49(3):453-61. PubMed ID: 18287274
[TBL] [Abstract][Full Text] [Related]
4. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging.
Liu Z; Niu G; Wang F; Chen X
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1483-94. PubMed ID: 19360404
[TBL] [Abstract][Full Text] [Related]
5. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.
Jackson AB; Nanda PK; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Chen X; Smith CJ
Nucl Med Biol; 2012 Apr; 39(3):377-87. PubMed ID: 22226021
[TBL] [Abstract][Full Text] [Related]
6. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
[TBL] [Abstract][Full Text] [Related]
7. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
8. A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging.
Yan Y; Chen K; Yang M; Sun X; Liu S; Chen X
Amino Acids; 2011 Jul; 41(2):439-47. PubMed ID: 20936525
[TBL] [Abstract][Full Text] [Related]
9. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
10. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots.
Hu K; Wang H; Tang G; Huang T; Tang X; Liang X; Yao S; Nie D
J Nucl Med; 2015 Aug; 56(8):1278-84. PubMed ID: 26112023
[TBL] [Abstract][Full Text] [Related]
12. Novel
Lucente E; Liu H; Liu Y; Hu X; Lacivita E; Leopoldo M; Cheng Z
Bioconjug Chem; 2018 May; 29(5):1595-1604. PubMed ID: 29587479
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic role of 99mTc-dual receptor targeted probe and targeted peptide bombesin (RGD-BBN) SPET/CT in the detection of malignant and benign breast tumors and axillary lymph nodes compared to ultrasound.
Ji T; Sun Y; Chen B; Ji B; Gao S; Ma Q; Cheng G; Zhang H
Hell J Nucl Med; 2015; 18(2):108-13. PubMed ID: 26187209
[TBL] [Abstract][Full Text] [Related]
14. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
Jiang L; Miao Z; Liu H; Ren G; Bao A; Cutler CS; Shi H; Cheng Z
Nucl Med Commun; 2013 Sep; 34(9):909-14. PubMed ID: 23708872
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, preclinical, and initial clinical evaluation of integrin α
Wen X; Wang R; Xu P; Shi M; Shang Q; Zeng X; Zeng X; Liu J; Wang X; Zhu Z; Guo Z; Chen X; Zhang J
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2023-2035. PubMed ID: 38376806
[TBL] [Abstract][Full Text] [Related]
16. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapy.
Cui L; Liu Z; Jin X; Jia B; Li F; Wang F
Nucl Med Biol; 2013 Feb; 40(2):182-9. PubMed ID: 23199569
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
